PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment

PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a $34.5 million market cap biotechnology company, announced Tuesday a new drug delivery platform designed to release GLP-1 receptor agonists subcutaneously for approximately 60 days, significantly extending the current standard of weekly injections for diabetes and weight management treatments. According to InvestingPro data, the company is currently operating with moderate debt levels while focusing on advancing its innovative drug delivery technologies.

The company’s polymer-lipid based matrix technology creates a protected drug reservoir that enables controlled and continuous medication delivery over an extended period. According to the company, the platform releases GLP-1 in a linear fashion, avoiding the burst release associated with current weekly formulations. While the technology shows promise, InvestingPro analysis indicates the company is quickly burning through cash, with a negative EBITDA of $27.7 million in the last twelve months.

"By harnessing our proprietary prolonged-release technology, we aim to provide patients with consistent, therapeutic levels of GLP-1 for approximately 60 days with a single administration," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid.

The company stated that its technology has been clinically validated in over 1,000 patients across two Phase 3 trials with no major safety concerns reported.

This development represents PolyPid’s expansion beyond its lead product candidate, D-PLEX100, which is being developed for the prevention of abdominal colorectal surgical site infections. The company expects to submit a New Drug Application for D-PLEX100 in early 2026.

The GLP-1 receptor agonist market is projected to grow substantially in coming years, with the company citing estimates that the diabetes and weight loss market could reach $100 billion by 2030. Analysts appear optimistic about PolyPid’s potential, setting price targets between $9 and $15, significantly above current trading levels. The company’s stock has shown strong momentum with an 11.5% gain year-to-date, though InvestingPro subscribers can access 8 additional key insights about the company’s financial health and market position.

PolyPid’s announcement comes as pharmaceutical companies compete to develop longer-lasting GLP-1 treatments to improve medication adherence for patients with type 2 diabetes and obesity.

The information in this article is based on a press release statement from PolyPid Ltd. Investors should note that the company’s next earnings report is scheduled for August 6, 2025, approximately 22 days away, which could be a significant catalyst for the stock price.

In other recent news, PolyPid Ltd. reported positive results from its Phase 3 SHIELD II trial for D-PLEX100, a product aimed at preventing surgical site infections. The trial met its primary efficacy endpoint, showing a significant reduction in infections, which has paved the way for a New Drug Application to the FDA in early 2026. JMP Securities has maintained a Market Outperform rating on PolyPid but lowered its price target to $14, citing potential dilution from new warrants. These warrants are expected to raise $26.7 million, supporting operations beyond the anticipated FDA approval of D-PLEX100. H.C. Wainwright has initiated coverage on PolyPid with a Buy rating, highlighting the potential of the company’s PLEX technology. In another development, PolyPid announced that its chairman, Jacob Harel, will step down at the upcoming shareholder meeting in June 2025. The company emphasized that this change is part of regular disclosure requirements and does not indicate any further management changes. Investors have shown positive reactions to these developments, with expectations for accelerated global partnership discussions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.